Vismed enters US trial for dry eye syndrome

USA-based drug development firm Lantibio and Swiss pharmaceutical company TRB Chemedica have initiated a Phase III clinical trial of the drug Vismed, a patented formulation of sodium hyaluronate, as a treatment for dry eye syndrome. The study is being carried out under Special Protocol Assessment criteria as dictated by the Food and Drug Administration.

The drug, which is already available in Europe, is being studied in the USA under Investigational New Drug application number 73,441, filed in June last year. If the current program is successful, the firms expect to file a New Drug Application with the FDA in 2008.